Pazopanib (BioDeep_00000182102)

   

human metabolite blood metabolite


代谢物信息卡片


5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide

化学式: C21H23N7O2S (437.1633858)
中文名称: 帕唑帕尼
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
InChI: InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)

描述信息

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor

同义名列表

6 个代谢物同义名

5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide; Pazopanibum; Pazopanib; GW786034; GW 78603; Votrient



数据库引用编号

9 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Karan Jadhav, Arvind Sirvi, Akash Janjal, Mahesh C Kashyap, Abhay T Sangamwar. Utilization of Lipophilic Salt and Phospholipid Complex in Lipid-Based Formulations to Modulate Drug Loading and Oral Bioavailability of Pazopanib. AAPS PharmSciTech. 2024 Mar; 25(3):59. doi: 10.1208/s12249-024-02780-3. [PMID: 38472682]
  • Xianhua She, Donghong Yin, Qian Guo, Yang Tang, Shuyun Wang, Xuyan Wang. Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis. Scientific reports. 2024 03; 14(1):5592. doi: 10.1038/s41598-024-56335-4. [PMID: 38454105]
  • Sameer J Nadaf, Suresh G Killedar, Vijay M Kumbar, Durgacharan A Bhagwat, Shailendra S Gurav. Pazopanib-laden lipid based nanovesicular delivery with augmented oral bioavailability and therapeutic efficacy against non-small cell lung cancer. International journal of pharmaceutics. 2022 Nov; 628(?):122287. doi: 10.1016/j.ijpharm.2022.122287. [PMID: 36257467]
  • Oktay Unsal, Osman Sütcüoğlu, Ozan Yazıcı. Dangerous interaction of bitter melon (Momordica charantia) with pazopanib: A case of acute pancreatitis. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2022 Mar; 28(2):486-488. doi: 10.1177/10781552211040725. [PMID: 34569860]
  • Stefanie D Krens, Sasja F Mulder, Nielka P van Erp. Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites. Cancer chemotherapy and pharmacology. 2022 02; 89(2):271-274. doi: 10.1007/s00280-021-04377-0. [PMID: 34853912]
  • Mamoru Hashimoto, Takahito Nakayama, Saizo Fujimoto, Shunsuke Inoguchi, Mitsuhisa Nishimoto, Takashi Kikuchi, Shogo Adomi, Eri Banno, Marco A De Velasco, Yoshitaka Saito, Nobutaka Shimizu, Yasunori Mori, Takafumi Minami, Kazutoshi Fujita, Masahiro Nozawa, Kazuhiro Nose, Kazuhiro Yoshimura, Hirotsugu Uemura. Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma. Anti-cancer drugs. 2022 01; 33(1):e818-e821. doi: 10.1097/cad.0000000000001230. [PMID: 34486537]
  • Bahadir Koylu, Fatih Tekin, Burak Yasin Aktas, Saadettin Kilickap, Deniz Koksal. Pazopanib-induced chylothorax in a patient with renal cell carcinoma. Anti-cancer drugs. 2022 01; 33(1):e555-e557. doi: 10.1097/cad.0000000000001172. [PMID: 34387587]
  • Asami Matsumoto, Ken Shiraiwa, Yosuke Suzuki, Kazuhiro Tanaka, Masanori Kawano, Tatsuya Iwasaki, Ryota Tanaka, Ryosuke Tatsuta, Hiroshi Tsumura, Hiroki Itoh. Sensitive quantification of free pazopanib using ultra-high performance liquid chromatography coupled to tandem mass spectrometry and assessment of clinical application. Journal of pharmaceutical and biomedical analysis. 2021 Nov; 206(?):114348. doi: 10.1016/j.jpba.2021.114348. [PMID: 34509660]
  • Jin-Wook Choi, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim, Susie Chin. Pazopanib-induced severe acute liver injury: A case report. Medicine. 2021 Nov; 100(46):e27731. doi: 10.1097/md.0000000000027731. [PMID: 34797298]
  • Simon Chowdhury, Jeffery R Infante, Robert Hawkins, Martin H Voss, Rodolfo Perini, Tobias Arkenau, Mark Voskoboynik, Paola Aimone, Isabelle Naeije, Albert Reising, David F McDermott. A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma. Clinical genitourinary cancer. 2021 10; 19(5):434-446. doi: 10.1016/j.clgc.2021.04.007. [PMID: 34006498]
  • Mustafa Erman, Bivas Biswas, Pongwut Danchaivijitr, Lingwu Chen, Yoke Fui Wong, Tarek Hashem, Chun Sen Lim, Bulent Karabulut, Hsiao-Jen Chung, Chandrasekhar Chikatapu, Sara Ingles, Khemaies Slimane, Ravindran Kanesvaran. Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study. BMC cancer. 2021 Sep; 21(1):1021. doi: 10.1186/s12885-021-08738-z. [PMID: 34521387]
  • Bulent Erdogan, Osman Kostek, Muhammet Bekir Hacioglu, Ali Gokyer, Ahmet Kucukarda, Erkan Ozcan, Ivo Gokmen, Sernaz Uzunoglu, Irfan Cicin. Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?. Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 2021 Sep; 26(5):2196-2201. doi: NULL. [PMID: 34761635]
  • Ondřej Fiala, Pavel Ostašov, Aneta Rozsypalová, Milan Hora, Ondřej Šorejs, Jan Šustr, Barbora Bendová, Ivan Trávníček, Jan Filipovský, Jindřich Fínek, Tomáš Büchler. Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line. Targeted oncology. 2021 09; 16(5):643-652. doi: 10.1007/s11523-021-00829-y. [PMID: 34363554]
  • Florian Janisch, Thomas Klotzbücher, Phillip Marks, Christina Kienapfel, Christian P Meyer, Hang Yu, Constantin Fühner, Tobias Hillemacher, Keiichiro Mori, Hadi Mostafei, Shahrokh F Shariat, Margit Fisch, Roland Dahlem, Michael Rink. Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors. World journal of urology. 2021 Aug; 39(8):2977-2985. doi: 10.1007/s00345-021-03628-2. [PMID: 33649869]
  • Aparna Sharma, Mayank Singh, Ravi Chauhan, Prabhat Singh Malik, Sachin Khurana, Sandeep Mathur, Sunesh Kumar, Vishnubhatla Sreenivas, Lalit Kumar. Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial. Gynecologic oncology. 2021 08; 162(2):382-388. doi: 10.1016/j.ygyno.2021.05.025. [PMID: 34088513]
  • M Eriksson, P Reichardt, H Joensuu, A Krarup-Hansen, O Hagberg, P Hohenberger, H Hagberg, L Hansson, T Foukakis, K Pulkkanen, S Bauer, D Goplen, P Blach Rossen, K Sundby Hall. Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST). ESMO open. 2021 08; 6(4):100217. doi: 10.1016/j.esmoop.2021.100217. [PMID: 34271307]
  • Nizar M Tannir, Kyriakos P Papadopoulos, Deborah J Wong, Raid Aljumaily, Annie Hung, Manuel Afable, Jong Seok Kim, David Ferry, Alexandra Drakaki, Johanna Bendell, Aung Naing. Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. International journal of cancer. 2021 07; 149(2):403-408. doi: 10.1002/ijc.33556. [PMID: 33709428]
  • Alper Topal, Sezin Sayın, Ali Gokyer, Ahmet Kucukarda, Osman Kostek, Muhammet Bekir Hacıoglu, Sernaz Uzunoglu, Bulent Erdogan, Irfan Cicin. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience. Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 2021 Jul; 26(4):1628-1634. doi: NULL. [PMID: 34565028]
  • Naoto Kanno, Kenta Nakahashi, Marina Shiikawa, Makoto Endo, Kenji Numahata, Satoshi Shiono. [Pneumothorax during Pazopanib Therapy in a Patient with Soft Tissue Sarcoma]. Gan to kagaku ryoho. Cancer & chemotherapy. 2021 Jul; 48(7):975-977. doi: NULL. [PMID: 34267040]
  • Nirmish Singla, Phillip Pierorazio, Mohamad Allaf, Yasser Ged. Re: Robert J. Motzer, Paul Russo, Naomi Haas, et al. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. Eur Urol 2021;79:334-8: PROTECTing Patients with Locally Advanced Kidney Cancer. European urology. 2021 07; 80(1):e33-e34. doi: 10.1016/j.eururo.2021.04.025. [PMID: 33962807]
  • Cristian Solano, Shrinjaya Thapa, Mohammad Muhsin Chisti. Adult Xp11.2 translocation renal cell carcinoma managed effectively with pazopanib. BMJ case reports. 2021 Jun; 14(6):. doi: 10.1136/bcr-2021-243058. [PMID: 34172479]
  • Joaquim Bellmunt, Emilio Esteban, Xabier García Del Muro, Juan Manuel Sepúlveda, Pablo Maroto, Enrique Gallardo, Aranzazu González Del Alba, Olatz Etxaniz, Marta Guix, Jose Luis González Larriba, Jose A Arranz, Miriam Redrado, Alfonso Calvo. Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. European urology oncology. 2021 06; 4(3):502-505. doi: 10.1016/j.euo.2019.07.014. [PMID: 31477526]
  • Ken Shiraiwa, Yosuke Suzuki, Kazuhiro Tanaka, Masanori Kawano, Tatsuya Iwasaki, Asami Matsumoto, Ryota Tanaka, Ryosuke Tatsuta, Hiroshi Tsumura, Hiroki Itoh. Development of a High-Throughput Quantification Method for Pazopanib Using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry and Its Clinical Application in Patients With Soft Tissue Tumors. Therapeutic drug monitoring. 2021 06; 43(3):416-421. doi: 10.1097/ftd.0000000000000821. [PMID: 33009287]
  • Darawan Rinchai, Elena Verzoni, Veronica Huber, Agata Cova, Paola Squarcina, Loris De Cecco, Filippo de Braud, Raffaele Ratta, Matteo Dugo, Luca Lalli, Viviana Vallacchi, Monica Rodolfo, Jessica Roelands, Chiara Castelli, Damien Chaussabel, Giuseppe Procopio, Davide Bedognetti, Licia Rivoltini. Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. Clinical and translational medicine. 2021 06; 11(6):e434. doi: 10.1002/ctm2.434. [PMID: 34185403]
  • Loïc Mourey, Félicien Le Louedec, Alain Ravaud, Marie-Noëlle Paludetto, Laurence Digue, Carlos Alberto Gomez-Roca, Thibaud Valentin, Laurent Balardy, Pascale Olivier, Bastien Cabarrou, Thomas Filleron, Etienne Chatelut. VOTRAGE study: Phase I dose-escalation study of pazopanib in unfit older patients. Journal of geriatric oncology. 2021 06; 12(5):759-764. doi: 10.1016/j.jgo.2021.02.006. [PMID: 33715996]
  • Yu V Vitruk, S L Semko, O A Voylenko, M V Pikul, T V Borikun, T V Zadvornyi, T M Yalovenko, E O Stakhovsky, O V Rossylna. Evaluation of response to tyrosine kinase inhibitors in renal cell carcinoma patients based on expression of miR-99b, -144, -210, -222, -302а and -377 in tumor tissue. Experimental oncology. 2021 06; 43(2):98-103. doi: 10.32471/exp-oncology.2312-8852.vol-43-no-2.16383. [PMID: 34190510]
  • Anil Kumar Yadav, Byeong-Churl Jang. Inhibition of Lipid Accumulation and Cyclooxygenase-2 Expression in Differentiating 3T3-L1 Preadipocytes by Pazopanib, a Multikinase Inhibitor. International journal of molecular sciences. 2021 May; 22(9):. doi: 10.3390/ijms22094884. [PMID: 34063048]
  • Ilya Tsimafeyeu, Yulia Tishova, Ruslan Zukov, Pavel Borisov, Anastasia Bondarenko, Kristina Zakurdaeva. Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Phase 2 Randomized Study FARETES. American journal of clinical oncology. 2021 04; 44(4):137-142. doi: 10.1097/coc.0000000000000797. [PMID: 33512910]
  • Nellie N Nafissi, Nina Karlin, Mark R Pittelkow, David J Dicaudo, Aaron R Mangold. Panniculitis in a patient with metastatic renal cell carcinoma on a tyrosine kinase inhibitor. Anti-cancer drugs. 2021 04; 32(4):474-475. doi: 10.1097/cad.0000000000000999. [PMID: 33290313]
  • Andrew L Laccetti, Benjamin Garmezy, Lianchun Xiao, Minas Economides, Aradhana Venkatesan, Jianjun Gao, Eric Jonasch, Paul Corn, Amado Zurita-Saavedra, Landon C Brown, Chester Kao, Emily N Kinsey, Rajan T Gupta, Michael R Harrison, Andrew J Armstrong, Daniel J George, Nizar Tannir, Pavlos Msaouel, Amishi Shah, Tian Zhang, Matthew T Campbell. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer medicine. 2021 04; 10(7):2341-2349. doi: 10.1002/cam4.3812. [PMID: 33650321]
  • Alessandra Mosca, Ugo De Giorgi, Giuseppe Procopio, Umberto Basso, Giacomo Cartenì, Melissa Bersanelli, Emanuele Naglieri, Luca Galli, Orazio Caffo, Giuseppe Fornarini, Francesco Boccardo, Camillo Porta. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study. Japanese journal of clinical oncology. 2021 Mar; 51(3):484-491. doi: 10.1093/jjco/hyaa193. [PMID: 33212499]
  • Francesco Pierantoni, Umberto Basso, Marco Maruzzo, Evelina Lamberti, Davide Bimbatti, Giuseppina Tierno, Eleonora Bergo, Antonella Brunello, Vittorina Zagonel. Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience. Journal of geriatric oncology. 2021 03; 12(2):290-297. doi: 10.1016/j.jgo.2020.09.009. [PMID: 32972885]
  • Robert J Motzer, Paul Russo, Naomi Haas, Christian Doehn, Frede Donskov, Marine Gross-Goupil, Sergei Varlamov, Evgeny Kopyltsov, Jae Lyun Lee, Ho Yeong Lim, Bohuslav Melichar, Milada Zemanova, Brian Rini, Toni K Choueiri, Lori Wood, M Neil Reaume, Arnulf Stenzl, Simon Chowdhury, Ray McDermott, Agnieszka Michael, Miguel Izquierdo, Paola Aimone, Hong Zhang, Cora N Sternberg. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. European urology. 2021 03; 79(3):334-338. doi: 10.1016/j.eururo.2020.12.029. [PMID: 33461782]
  • Michael Staehler, Andrej Panic, Peter J Goebell, Marie Merling, Karin Potthoff, Edwin Herrmann, Patrick de Geeter, Corinne Vannier, Cathrin Hogrefe, Norbert Marschner, Viktor Grünwald. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial. International journal of cancer. 2021 02; 148(4):950-960. doi: 10.1002/ijc.33238. [PMID: 32738823]
  • Yuanyuan Wang, Hao Ma, Jiaxuan Huang, Zhengguang Yao, Jianqiang Yu, Wannian Zhang, Lichao Zhang, Zhibin Wang, Chunlin Zhuang. Discovery of bardoxolone derivatives as novel orally active necroptosis inhibitors. European journal of medicinal chemistry. 2021 Feb; 212(?):113030. doi: 10.1016/j.ejmech.2020.113030. [PMID: 33248849]
  • Leo L Tsai, Rupal S Bhatt, Meaghan F Strob, Opeyemi A Jegede, Maryellen R M Sun, David C Alsop, Paul Catalano, David McDermott, Philip M Robson, Michael B Atkins, Ivan Pedrosa. Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma. Radiology. 2021 02; 298(2):332-340. doi: 10.1148/radiol.2020201763. [PMID: 33258745]
  • Shinya Takasaki, Yoshihide Kawasaki, Masafumi Kikuchi, Akihiro Ito, Hiroaki Yamaguchi, Nariyasu Mano. Clinical Importance of Plasma Drug Concentration of Oral Molecular Targeted Drugs for Renal Cell Carcinoma. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 2021 ; 24(?):127-136. doi: 10.18433/jpps31816. [PMID: 34559626]
  • J Gomolčáková, B Brezinová, P Dubovan, S Jurišová, K Rejlekova, M Chovanec, J Mardiak, M Mego. Targeted therapy in Xp11 translocation renal cell carcinoma. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 2021; 34(2):137-140. doi: 10.48095/ccko2021137. [PMID: 33906362]
  • Stefano Capri, Camillo Porta, Claudia Condorelli, Eleonora Premoli, Ankur Khare, Manik Kalra, Niraj Modi, Barbara Ratto. An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy. Journal of medical economics. 2020 Dec; 23(12):1579-1587. doi: 10.1080/13696998.2020.1839240. [PMID: 33079593]
  • Christopher G Wood, James E Ferguson, Joel S Parker, Dominic T Moore, Jennifer G Whisenant, Susan J Maygarden, Eric M Wallen, William Y Kim, Mathew I Milowsky, Kathryn E Beckermann, Nancy B Davis, Scott M Haake, Jose A Karam, Dante S Bortone, Benjamin G Vincent, Thomas Powles, W Kimryn Rathmell. Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. JCI insight. 2020 11; 5(22):. doi: 10.1172/jci.insight.132852. [PMID: 33208553]
  • Fabian Hofmann, Eu Chang Hwang, Thomas Bl Lam, Axel Bex, Yuhong Yuan, Lorenzo So Marconi, Börje Ljungberg. Targeted therapy for metastatic renal cell carcinoma. The Cochrane database of systematic reviews. 2020 10; 10(?):CD012796. doi: 10.1002/14651858.cd012796.pub2. [PMID: 33058158]
  • Zsófia Küronya, Mihály Dániel Szőnyi, Krisztián Nagyiványi, Fruzsina Gyergyay, Lajos Géczi, Barna Budai, Tamás Martin, Andrea Ladányi, Edina Kiss, Krisztina Biró. Predictive Markers of First Line Pazopanib Treatment in Kidney Cancer. Pathology oncology research : POR. 2020 Oct; 26(4):2475-2481. doi: 10.1007/s12253-020-00853-9. [PMID: 32572819]
  • Guilherme Nader Marta, Pedro Isaacsson Velho, Renata R C Bonadio, Mirella Nardo, Sheila F Faraj, Manoel Carlos L de Azevedo Souza, David Q B Muniz, Diogo Assed Bastos, Carlos Dzik. Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma. Pathology oncology research : POR. 2020 Oct; 26(4):2489-2497. doi: 10.1007/s12253-020-00840-0. [PMID: 32583330]
  • Nizar M Tannir, Pavlos Msaouel, Jeremy A Ross, Catherine E Devine, Anuradha Chandramohan, Graciela M Nogueras Gonzalez, Xuemei Wang, Jennifer Wang, Paul G Corn, Zita D Lim, Lisa Pruitt, Jose A Karam, Christopher G Wood, Amado J Zurita. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. European urology oncology. 2020 10; 3(5):687-694. doi: 10.1016/j.euo.2019.06.004. [PMID: 31272939]
  • Marina Deuker, Felix K H Chun, Pierre I Karakiewicz. Second-line tyrosine kinase inhibitor-therapy after immunotherapy-failure. Current opinion in supportive and palliative care. 2020 09; 14(3):276-285. doi: 10.1097/spc.0000000000000519. [PMID: 32769619]
  • Pierangela Sepe, Antonia Martinetti, Alessia Mennitto, Elena Verzoni, Melanie Claps, Alessandra Raimondi, Elisa Sottotetti, Paolo Grassi, Valentina Guadalupi, Marco Stellato, Emma Zattarin, Massimo Di Maio, Giuseppe Procopio. Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study). American journal of clinical oncology. 2020 09; 43(9):621-627. doi: 10.1097/coc.0000000000000719. [PMID: 32889831]
  • Greet Van De Sijpe, Benoit Beuselinck, Tine Van Nieuwenhuyse, Roxanne Poncelet, Oliver Bechter, Maarten Albersen, Eduard Roussel, Marcella Baldewijns, Jan Tack, Isabel Spriet. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma. European journal of clinical pharmacology. 2020 Sep; 76(9):1273-1280. doi: 10.1007/s00228-020-02902-3. [PMID: 32474662]
  • Gianluca Perego, Paolo Barzaghi, Ivano Vavassori, Fausto Petrelli. Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy. Medical oncology (Northwood, London, England). 2020 Aug; 37(9):81. doi: 10.1007/s12032-020-01408-3. [PMID: 32767163]
  • Darija Kuruc Poje, Nada Božina, Livija Šimičević, Igor Žabić. Severe hyperglycaemia following pazopanib treatment: The role of drug-drug-gene interactions in a patient with metastatic renal cell carcinoma-A case report. Journal of clinical pharmacy and therapeutics. 2020 Aug; 45(4):628-631. doi: 10.1111/jcpt.13160. [PMID: 32369219]
  • Ying Yan Zhong, Luke McLean, Andrew Buckle, Shankar Siva, Ben Tran. Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab. The Canadian journal of urology. 2020 08; 27(4):10339-10341. doi: NULL. [PMID: 32861263]
  • Yuqing Li, Yanyun Shen, Zhidong Zhu, Hui Wen, Chenchen Feng. Comprehensive analysis of copy number variance and sensitivity to common targeted therapy in clear cell renal cell carcinoma: In silico analysis with in vitro validation. Cancer medicine. 2020 08; 9(16):6020-6029. doi: 10.1002/cam4.3281. [PMID: 32628820]
  • Lorenz Haaker, Loesia Tryssesoone, Inne Renders, Annelies Verbiest, Evelyne Lerut, Marcella Baldewijns, Claire Bourgain, Eduard Roussel, Heidi Van den Bulck, Wim Wynendaele, Brigitte Laguerre, Nathalie Rioux-Leclercq, Stéphane Oudard, Annouschka Laenen, Philip R Debruyne, Maarten Albersen, Benoit Beuselinck. Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors. Urologic oncology. 2020 08; 38(8):686.e1-686.e9. doi: 10.1016/j.urolonc.2020.04.031. [PMID: 32430250]
  • Robert Hawkins, Kate Fife, Michael Hurst, Meng Wang, Niroshini Naicker, Sarah Nolasco, Tim Eisen, Athena Matakidou, Jason Gordon. Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK. BMC cancer. 2020 Jul; 20(1):670. doi: 10.1186/s12885-020-07154-z. [PMID: 32680483]
  • Yukinori Harada, Shintaro Kakimoto, Taro Shimizu. Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma. BMJ case reports. 2020 Jul; 13(7):. doi: 10.1136/bcr-2020-235177. [PMID: 32641305]
  • Benoit Beuselinck, Steven Pans, Jurgen Bielen, Liesbeth De Wever, Nathalie Noppe, Geert Vanderschueren, Frederik De Keyzer, Marcella Baldewijns, Evelyne Lerut, Annouschka Laenen, Annelies Verbiest, Eduard Roussel, Maarten Albersen, Vincent Vandecaveye. Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors. Acta oncologica (Stockholm, Sweden). 2020 Jul; 59(7):818-824. doi: 10.1080/0284186x.2020.1750696. [PMID: 32297532]
  • Nazım C Demircan, Özkan Alan, Tuğba Başoğlu Tüylü, Tuğba Akın Telli, Rukiye Arıkan, Furkan C Çiçek, Özlem Ercelep, Mehmet A Öztürk, İlknur Alsan Çetin, Rabia Ergelen, İlker Tinay, Nalan Akgül Babacan, Serap Kaya, Faysal Dane, Perran F Yumuk. Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2020 Jul; 26(5):1147-1155. doi: 10.1177/1078155219890032. [PMID: 31793376]
  • Stefanie L Groenland, Ruben A G van Eerden, Remy B Verheijen, Niels de Vries, Bas Thijssen, Hilde Rosing, Jos H Beijnen, Stijn L W Koolen, Ron H J Mathijssen, Alwin D R Huitema, Neeltje Steeghs. Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients. Clinical pharmacokinetics. 2020 07; 59(7):941-948. doi: 10.1007/s40262-020-00863-5. [PMID: 32020530]
  • Onur Bas, Aral Ozbek, Denizcan Guven, Oktay Aktepe, Levent Kılıc, Neyran Kertmen, Mustafa Erman. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2020 Jul; 26(5):1230-1233. doi: 10.1177/1078155219884113. [PMID: 31735133]
  • Mailys De Sousa Mendes, Oliver Hatley, Katherine Linda Gill, Karen Rowland Yeo, Alice Ban Ke. A physiologically based pharmacokinetic - pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug-drug interactions of paclitaxel in cancer patients. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2020 Jul; 150(?):105355. doi: 10.1016/j.ejps.2020.105355. [PMID: 32438273]
  • Nicolas Epaillard, Audrey Simonaggio, Reza Elaidi, Fouzia Azzouz, Elena Braychenko, Constance Thibault, Cheng-Ming Sun, Marco Moreira, Stéphane Oudard, Yann-Alexandre Vano. BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. Bulletin du cancer. 2020 Jun; 107(5S):eS22-eS27. doi: 10.1016/s0007-4551(20)30283-6. [PMID: 32620212]
  • Shiva Gupta, Hyunseon C Kang, Jia Sun, Marc R Matrana, Nizar M Tannir, Haesun Choi. Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC). Abdominal radiology (New York). 2020 06; 45(6):1872-1882. doi: 10.1007/s00261-019-02354-z. [PMID: 31822966]
  • Hiroyuki Tanaka, Hiroaki Hiraga, Yoh Takekuma, Toru Harabayashi, Satoshi Nagamori, Masayuki Endo, Mitsuru Sugawara. Possibility for Dose Optimization of Pazopanib from Its Plasma Concentration in Japanese Patients with Cancer. Biological & pharmaceutical bulletin. 2020 May; 43(5):762-766. doi: 10.1248/bpb.b19-00560. [PMID: 32115446]
  • Yulian Mytsyk, Serhiy Pasichnyk, Ihor Dutka, Ihor Dats, Dmytro Vorobets, Michał Skrzypczyk, Yerzhan Uteuliyev, Andrea Botikova, Katarina Gazdikova, Peter Kubatka, Peter Urdzik, Peter Kruzliak. Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response. Clinical and experimental medicine. 2020 May; 20(2):277-287. doi: 10.1007/s10238-020-00612-9. [PMID: 32026157]
  • Pablo S Sierra, Maurício D Cordeiro, Emanuel V Albuquerque, Diogo A Bastos, Renata C Bonadio, Alvaro S Sarkis, Alexandre Cavalcante, Jose Pontes, Rafael F Coelho, William C Nahas. Oncologic Outcomes in Young Adults With Kidney Cancer Treated During the Targeted Therapy Era. Clinical genitourinary cancer. 2020 04; 18(2):e134-e144. doi: 10.1016/j.clgc.2019.09.012. [PMID: 31980410]
  • Jean-Luc Raoul, Julien Edeline, Marine Gilabert, Hélène Senellart, Jean-Sébastien Frenel. [Proton pump inhibitors and cancers: A hazardous association?]. Bulletin du cancer. 2020 Apr; 107(4):458-464. doi: 10.1016/j.bulcan.2019.12.009. [PMID: 32057465]
  • Camille Azam, Pauline Claraz, Christine Chevreau, Camille Vinson, Ewa Cottura, Loïc Mourey, Damien Pouessel, Selena Guibaud, Olivia Pollet, Magali Le Goff, Catherine Bardies, Véronique Pelagatti, Jean Marie Canonge, Florent Puisset. Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors. European journal of clinical pharmacology. 2020 Apr; 76(4):579-587. doi: 10.1007/s00228-020-02828-w. [PMID: 31932871]
  • Xinan Sheng, Jie Jin, Zhisong He, Yiran Huang, Aiping Zhou, Jinwan Wang, Xiubao Ren, Dingwei Ye, Xu Zhang, Shukui Qin, Fangjian Zhou, Binhui Wang, Jun Guo. Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies. BMC cancer. 2020 Mar; 20(1):219. doi: 10.1186/s12885-020-6708-8. [PMID: 32171288]
  • Lucas Zarling, Hamid Emamekhoo, Gauri Bhutani, Timothy Ziemlewicz, Kristina A Matkowskyj, Christos E Kyriakopoulos. Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report. Anticancer research. 2020 Mar; 40(3):1527-1534. doi: 10.21873/anticanres.14098. [PMID: 32132053]
  • Stefano Fogli, Camillo Porta, Marzia Del Re, Stefania Crucitta, Giulia Gianfilippo, Romano Danesi, Brian I Rini, Manuela Schmidinger. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer treatment reviews. 2020 Mar; 84(?):101966. doi: 10.1016/j.ctrv.2020.101966. [PMID: 32044644]
  • G K Raju, Karthik Gurumurthi, Reuben Domike, Harpreet Singh, Chana Weinstock, Paul Kluetz, Richard Pazdur, Janet Woodcock. Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: Renal Cell Carcinoma. Clinical pharmacology and therapeutics. 2020 03; 107(3):495-506. doi: 10.1002/cpt.1589. [PMID: 31355920]
  • Carsten Nieder, Astrid Dalhaug, Adam R Pawinski. Management of Patients With Metastatic Renal Cell Cancer and Bone Metastases. In vivo (Athens, Greece). 2020 Mar; 34(2):675-678. doi: 10.21873/invivo.11822. [PMID: 32111768]
  • Chao Wang, Yuning Wang, Tianyu Hong, Bing Cheng, Sishun Gan, Linbao Chen, Jing Zhang, Li Zuo, Jian Li, Xingang Cui. Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma. Cell death & disease. 2020 02; 11(2):117. doi: 10.1038/s41419-020-2306-6. [PMID: 32051393]
  • Jakob N Henriksen, Pernille Bøttger, Carina K Hermansen, Søren A Ladefoged, Peter H Nissen, Stephen Hamilton-Dutoit, Thomas L Fink, Frede Donskov. Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes. Clinical genitourinary cancer. 2020 02; 18(1):62-68.e2. doi: 10.1016/j.clgc.2019.09.013. [PMID: 31640912]
  • Xiting Cao, Derek Tang, Barbara Ratto, Austin Poole, Shoba Ravichandran, Lixian Jin, Wei Gao, Elyse Swallow, Nicholas J Vogelzang. Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma. Clinical genitourinary cancer. 2020 02; 18(1):e37-e45. doi: 10.1016/j.clgc.2019.10.010. [PMID: 31727510]
  • Kim Westerdijk, Ingrid M E Desar, Neeltje Steeghs, Winette T A van der Graaf, Nielka P van Erp. Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose. British journal of clinical pharmacology. 2020 02; 86(2):258-273. doi: 10.1111/bcp.14185. [PMID: 31782166]
  • Marie-Noëlle Paludetto, Jean-Luc Stigliani, Anne Robert, Vania Bernardes-Génisson, Etienne Chatelut, Florent Puisset, Cécile Arellano. Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug-Drug Interactions in Vitro and in Patient Samples. Chemical research in toxicology. 2020 01; 33(1):181-190. doi: 10.1021/acs.chemrestox.9b00205. [PMID: 31535851]
  • Ivana Puliafito, Alessio Russo, Dorotea Sciacca, Caterina Puglisi, Dario Giuffrida. Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report. Journal of medical case reports. 2020 Jan; 14(1):7. doi: 10.1186/s13256-019-2318-y. [PMID: 31924259]
  • M Ekenel, S Karabulut, I Cil, A Zırtıloglu, E Aydın, D Tural. Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience. Actas urologicas espanolas. 2020 Jan; 44(1):27-33. doi: 10.1016/j.acuro.2019.06.007. [PMID: 31744648]
  • Annelies Verbiest, Vincent Van Hoef, Cristina Rodriguez-Antona, Jesús García-Donas, Osvaldo Graña-Castro, Maarten Albersen, Marcella Baldewijns, Annouschka Laenen, Eduard Roussel, Patrick Schöffski, Agnieszka Wozniak, Stefano Caruso, Gabrielle Couchy, Jessica Zucman-Rossi, Benoit Beuselinck. MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets. PloS one. 2020; 15(9):e0238809. doi: 10.1371/journal.pone.0238809. [PMID: 32915890]
  • Jill Stein, Mohammed Milhem, Daniel Vaena. Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2020 Jan; 26(1):232-235. doi: 10.1177/1078155219841108. [PMID: 30961437]
  • Martin Schostak, Patrick de Geeter, Thomas Decker, Anna Resch, Claudia Quiering, Stephan Schmitz. A Phase 4 Study of Everolimus to Evaluate Efficacy and Safety in Patients with Metastatic Renal-Cell Carcinoma after Failure of First-Line Sunitinib or Pazopanib (SUNPAZ). Urologia internationalis. 2020; 104(3-4):263-268. doi: 10.1159/000503870. [PMID: 31726458]
  • Kazutaka Maruo, Atsushi Takahashi, Hidetoshi Tabata, Akio Takayanagi, Yoshio Takagi. [RENAL CELL CARCINOMA METASTASIS TO BLADDER DURING MOLECULAR TARGETED THERAPY WITH PAZOPANIB: REPORT OF TWO CASES]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology. 2020; 111(2):58-61. doi: 10.5980/jpnjurol.111.58. [PMID: 33883361]
  • Ghada Elshimy, Anand Gandhi, Rong Guo, Ricardo Correa. Tyrosine Kinase Inhibitors' Newly Reported Endocrine Side Effect: Pazopanib-Induced Primary Adrenal Insufficiency in a Patient With Metastatic Renal Cell Cancer. Journal of investigative medicine high impact case reports. 2020 Jan; 8(?):2324709620936808. doi: 10.1177/2324709620936808. [PMID: 32583692]
  • Shinya Takasaki, Hisanobu Adachi, Yoshihide Kawasaki, Masafumi Kikuchi, Akihiro Ito, Nariyasu Mano. Importance of Therapeutic Drug Monitoring to Detect Drug Interaction between Pazopanib and Warfarin: A Case Report. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 2020; 23(?):200-205. doi: 10.18433/jpps30868. [PMID: 32407286]
  • Gregory T Sneed, Sukdong Lee, Jamie N Brown, Julia M Hammond. The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review. Clinical genitourinary cancer. 2019 12; 17(6):419-424. doi: 10.1016/j.clgc.2019.09.001. [PMID: 31585694]
  • David Queiroz Muniz, Barbara Ratto, Hongbo Yang, Jing Zhao, Madeline Jenkins, James Signorovitch, Luca Dezzani, Pamela Salman, Mauricio Lema Medina, Diego Lopera, Guillermo Lerzo, Cesar Del Castillo, Matias Chacon, Ana Martin, Saul Campos-Gomez. Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America. Advances in therapy. 2019 12; 36(12):3446-3457. doi: 10.1007/s12325-019-01109-y. [PMID: 31630333]
  • Cora N Sternberg, Robert J Motzer, Thomas E Hutson, Toni K Choueiri, Christian Kollmannsberger, Georg A Bjarnason, Paul Nathan, Camillo Porta, Viktor Grünwald, Luca Dezzani, Jackie Han, Nizar M Tannir. COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. Clinical genitourinary cancer. 2019 12; 17(6):425-435.e4. doi: 10.1016/j.clgc.2019.01.015. [PMID: 31601514]
  • Nilgun Yildirim, Murat Gonen, Ferhat Balgetir, Muhammed Burak Er. Fatal Acute Motor Axonal Neuropathy Induced by Nivolumab: A Case Report and Literature Review. Clinical genitourinary cancer. 2019 12; 17(6):e1104-e1107. doi: 10.1016/j.clgc.2019.07.020. [PMID: 31471269]
  • Mario Vaccaro, Gabriella Riso, Domenica Altavilla, Serafinella P Cannavò. Eyelashes depigmentation following treatment with pazopanib for metastatic renal cell carcinoma. Dermatologic therapy. 2019 11; 32(6):e13140. doi: 10.1111/dth.13140. [PMID: 31664777]
  • Yasuyoshi Okamura, Tomoaki Terakawa, Mariko Sakamoto, Yukari Bando, Kotaro Suzuki, Takuto Hara, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa. Presurgical Pazopanib Improves Surgical Outcomes for Renal Cell Carcinoma With High-level IVC Tumor Thrombosis. In vivo (Athens, Greece). 2019 Nov; 33(6):2013-2019. doi: 10.21873/invivo.11698. [PMID: 31662532]
  • Daniel J George, Susan Halabi, Patrick Healy, Ian Barak, Carolyn Winters, Monika Anand, Rhonda Wilder, Melissa Klein, Elia Martinez, Andrew B Nixon, Michael R Harrison, Russell Szmulewitz, Andrew J Armstrong. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. The Prostate. 2019 11; 79(15):1752-1761. doi: 10.1002/pros.23899. [PMID: 31497882]
  • Sherrie L Aspinall, Xinhua Zhao, Mark C Geraci, Chester B Good, Francesca E Cunningham, Bernadette B Heron, Daniel Becker, Steve Lee, Vinay Prasad. Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration. Cancer medicine. 2019 11; 8(15):6651-6661. doi: 10.1002/cam4.2531. [PMID: 31536684]
  • Karin Purshouse, Sarah Chamberlain, Maria Soares, Mark Tuthill, Andrew Protheroe, David R Mole. Case report of oxalate nephropathy in a patient with pancreatic metastases from renal carcinoma. BMC cancer. 2019 Oct; 19(1):967. doi: 10.1186/s12885-019-6215-y. [PMID: 31623580]
  • Manuela Schmidinger, Renate Pichler, Wolfgang Loidl, Thomas Bauernhofer, Matthias Kretz, Christoph Tinchon, Dora Niedersüß-Beke, Gottfried Pfleger, Clemens Georg Wiesinger, Ursula Vogl, Michael Mitterberger, Herbert Stöger, Gennadi Tulchiner, Franz Kratochvill, Hanno Gerritsmann, Bernhard Mraz, Martin Marszalek. Real-World Evidence Data on Metastatic Renal-Cell Carcinoma Treatment in Austria: The RELACS Study. Clinical genitourinary cancer. 2019 10; 17(5):e957-e967. doi: 10.1016/j.clgc.2019.05.017. [PMID: 31235275]
  • C Vargas, C Balmaceda, F Rodríguez, R Rojas, A Giglio, M A Espinoza. Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison. Expert review of pharmacoeconomics & outcomes research. 2019 Oct; 19(5):609-617. doi: 10.1080/14737167.2019.1580572. [PMID: 30758237]
  • Annelies Verbiest, Inne Renders, Stefano Caruso, Gabrielle Couchy, Sylvie Job, Annouschka Laenen, Virginie Verkarre, Nathalie Rioux-Leclercq, Patrick Schöffski, Yann Vano, Reza-Thierry Elaidi, Evelyne Lerut, Maarten Albersen, Stéphane Oudard, Wolf-Hervé Fridman, Catherine Sautès-Fridman, Laurence Albigès, Agnieszka Wozniak, Jessica Zucman-Rossi, Benoit Beuselinck. Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. Clinical genitourinary cancer. 2019 10; 17(5):e981-e994. doi: 10.1016/j.clgc.2019.05.009. [PMID: 31229459]
  • Yuanyuan Zhang, Jonathan Schoenhals, Alana Christie, Osama Mohamad, Chiachien Wang, Isaac Bowman, Nirmish Singla, Hans Hammers, Kevin Courtney, Aditya Bagrodia, Vitaly Margulis, Neil Desai, Aurelie Garant, Hak Choy, Robert Timmerman, James Brugarolas, Raquibul Hannan. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. International journal of radiation oncology, biology, physics. 2019 10; 105(2):367-375. doi: 10.1016/j.ijrobp.2019.07.023. [PMID: 31377159]
  • Prabhsimranjot Singh, Robert N DʼAngelo, Victor Huang. Pazopanib-Associated Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome: A Case Report. American journal of therapeutics. 2019 Sep; 26(5):e636-e638. doi: 10.1097/mjt.0000000000000840. [PMID: 30946042]
  • Isandra Oliveira Meirelles, Dulce Helena Nunes Couto, Rodrigo Saar da Costa. [Cost-effectiveness between pazopanib and sunitinib for metastatic renal cancer from the perspective of the Brazilian Unified National Health System]. Cadernos de saude publica. 2019 Aug; 35(8):e00108218. doi: 10.1590/0102-311x00108218. [PMID: 31460611]